Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Keryx Biopharm Inc (NQ: KERX )

3.360 USD UNCHANGED
Last Price Updated: 6:12 PM EST, Dec 12, 2018 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.360
Bid (Size) 2.510 (10)
Ask (Size) 3.400 (5)
Prev. Close 3.360
Today's Range 3.360 - 3.360
52wk Range N/A - N/A
Shares Outstanding 120,378,658
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
From PR Newswire
Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor... 
From GlobeNewswire News Releases

Performance

More News

Read More
Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
From GlobeNewswire News Releases
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
From GlobeNewswire News Releases
Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate — Research Highlights Growth, Re
From GlobeNewswire News Releases
Akebia Therapeutics Shareholders Approve Merger with Keryx
From Business Wire News Releases
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
From Business Wire News Releases
Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
From Business Wire News Releases
Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results
From GlobeNewswire News Releases
Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger, Raymond James Says
Tags AKBA Market News Price Target
From Benzinga
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.